Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Pyxis Oncology, Inc. (PYXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/27/2023 4 Wadhane Jitendra (Chief Accounting Officer) has filed a Form 4 on Pyxis Oncology, Inc.
Txns: Bought 2,500 shares @ $1.87, valued at $4.7k
09/27/2023 4 Connealy Pamela Ann (CFO and COO) has filed a Form 4 on Pyxis Oncology, Inc.
Txns: Bought 6,426 shares @ $1.8468, valued at $11.9k
09/26/2023 4 Dupont Jakob (Director) has filed a Form 4 on Pyxis Oncology, Inc.
Txns: Granted 392,461 options to buy @ $1.6, valued at $627.9k
08/25/2023 4 Dupont Jakob (Director) has filed a Form 4 on Pyxis Oncology, Inc.
Txns: Granted 5,879 options to buy @ $26.61, valued at $156.4k
Granted 3,534 options to buy @ $26.61, valued at $94k
Granted 17,250 options to buy @ $15.37, valued at $265.1k
08/25/2023 3 Dupont Jakob (Director) has filed a Form 3 on Pyxis Oncology, Inc.
08/25/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/23/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/23/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
08/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/23/2023 8-K Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...
Docs: "Pyxis Oncology Successfully Completes Acquisition of Apexigen August 23, 2023 Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 Guidance on development strategy, timelines and milestones for the newly acquired Phase 2 sotigalimab CD40 agonist to be shared in 4Q23 BOSTON, Aug. 23, 2023 -- Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the successful c..."
08/11/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/11/2023 8-K Quarterly results
Docs: "Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen transaction anticipated to close later in August Strong balance sheet with $144 million in cash and short-term investments supports operations into 1H 2025 BOSTON, August 11, 2023 – Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update. Pyxis Oncology ended the second quarter of 2023 with approximately $144.1 million in cash, cas..."
08/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The Merger On May 23, 2023, Pyxis Oncology, Inc., a Delaware corporation , entered into an Agreement and Plan of Merger , by and among the Company, Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company , and Apexigen, Inc., a Delaware corporation , pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Apexigen , with Apexigen surviving such Merger as a wholly-owned subsidiary of the Company. Definitions for the capitalized terms used in this section are provided herein. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger : a) Each share of common stock, par value $0.0001 per share, of..."
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/28/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/21/2023 144 Form 144 - Report of proposed sale of securities:
07/11/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/30/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/29/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
06/16/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 S-4 Form S-4 - Registration of securities, business combinations:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
05/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/25/2023 425 Form 425 - Prospectuses and communications, business combinations:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy